N8659
Nimustine hydrochloride
solid
Synonym(s):
N′-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea hydrochloride
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C9H13ClN6O2
CAS Number:
Molecular Weight:
272.69
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
form
solid
SMILES string
Cl.Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1
InChI
1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H
InChI key
KPMKNHGAPDCYLP-UHFFFAOYSA-N
Application
Nimustine hydrochloride is an antineoplastic.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Acute Tox. 3 Oral
Storage Class
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nancy Berte et al.
Molecular cancer therapeutics, 15(11), 2665-2678 (2016-11-04)
Malignant gliomas exhibit a high level of intrinsic and acquired drug resistance and have a dismal prognosis. First- and second-line therapeutics for glioblastomas are alkylating agents, including the chloroethylating nitrosoureas (CNU) lomustine, nimustine, fotemustine, and carmustine. These agents target the
A Shiraishi et al.
Carcinogenesis, 21(10), 1879-1883 (2000-10-07)
O(6)-methylguanine-DNA methyltransferase plays vital roles in preventing induction of mutations and cancer as well as cell death related to alkylating agents. Mice defective in the MGMT: gene, encoding the methyltransferase, were used to evaluate cell death-inducing and tumorigenic activities of
Marina Pajic et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(22), 7020-7033 (2017-08-20)
Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse.Experimental Design: We studied responses to various mono- and bifunctional alkylating agents in a genetically engineered mouse model for BRCA1/p53-mutant breast cancer.